<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2396">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129969</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-110401</org_study_id>
    <nct_id>NCT05129969</nct_id>
  </id_info>
  <brief_title>Registry Platform Ovarian and Endometrial Cancer</brief_title>
  <acronym>SMARAGD</acronym>
  <official_title>SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to set up a national, prospective, longitudinal, multicenter&#xD;
      cohort study, a tumor registry platform, to document uniform data on characteristics,&#xD;
      molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes&#xD;
      and to establish a decentralized biobank for patients with advanced or metastatic ovarian&#xD;
      cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SMARAGD is a national, prospective, open-label, longitudinal, non-interventional multicenter&#xD;
      cohort study (tumour registry platform) to describe treatment in routine clinical practice of&#xD;
      ovarian, fallopian tube, primary peritoneal and endometrial patients in routine care in&#xD;
      Germany.&#xD;
&#xD;
      The registry will follow patients for up to three years with the aim to identify common&#xD;
      therapeutic sequences and changes in the treatment of the disease. At inclusion, data in&#xD;
      patient characteristics, comorbidities, tumor characteristics and previous treatments are&#xD;
      collected. During the course of observation data on all systemic treatments, radiotherapies,&#xD;
      surgeries, and outcome are documented.&#xD;
&#xD;
      Health-related quality of life (HRQoL) will be evaluated for up to three years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2021</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Course of treatment (treatment reality).</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of anamnestic data and therapy sequences.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response.</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Documentation of overall survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome, PRO).</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Functional Assessment of Cancer Therapy - Ovarian (FACT-O), a 39 item questionnaire covering Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being and Ovarian Cancer Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome, PRO).</measure>
    <time_frame>3 years per patient</time_frame>
    <description>Functional Assessment of Cancer Therapy - Endometrial (FACT-En), a 43 item questionnaire covering Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being and Endometrial Cancer Subscale</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Ovary Neoplasm</condition>
  <condition>Endometrial Neoplasms</condition>
  <condition>Carcinoma, Ovarian</condition>
  <condition>Carcinoma</condition>
  <condition>Neoplasm, Ovarian</condition>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <description>Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):&#xD;
with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment, independent of the treatment intention (adjuvant/curative or palliative) or&#xD;
with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting their systemic treatment for first recurrent/relapsed disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <description>Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physician's choice according to patient's needs.</intervention_name>
    <description>Routine care as per site standard.</description>
    <arm_group_label>Endometrial cancer</arm_group_label>
    <arm_group_label>Ovarian cancer</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      All patients will be asked to give additional informed consent agreeing that their routinely&#xD;
      collected tumor samples could be used for further translational research. For the&#xD;
      decentralized biobank, pathological samples will remain with the local pathologist until&#xD;
      scientific translational question arise. Future translational research projects that will&#xD;
      develop during the project will be described in detail in independent research proposal and&#xD;
      reviewed by an ethics committee.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female patients with (metastatic) ovarian cancer (FIGO stage IIb-IV) or (metastatic)&#xD;
        endometrial cancer (FIGO stage III-IV) starting systemic treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and&#xD;
             primary peritoneal cancer):&#xD;
&#xD;
               -  patients with FIGO stage IIb-IV OC who are starting systemic treatment or&#xD;
&#xD;
               -  patients with recurrent/relapsed disease, who received any previous systemic&#xD;
                  anti-tumor treatment and who are now starting systemic treatment for&#xD;
                  recurrent/relapsed disease.&#xD;
&#xD;
          -  Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting&#xD;
             systemic first-line therapy.&#xD;
&#xD;
          -  Signed and dated informed consent (IC):&#xD;
&#xD;
               -  Patients participating in PRO module: IC before first therapy cycle&#xD;
&#xD;
               -  Patients not participating in PRO module: IC no later than six weeks after start&#xD;
                  of first therapy cycle&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed early-stage OC (FIGO stage I-IIa)&#xD;
&#xD;
          -  Low grade mOC OR&#xD;
&#xD;
          -  Early-stage EC (FIGO stage I-II)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Ovarian or endometrial cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Decker, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Ravensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingolf Juhasz-Böss, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elmar Stickeler, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Aachen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk Watermann, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anja Welt, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Essen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achim Wöckel, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Würzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>iOMEDICO AG</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites all over Germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Registry</keyword>
  <keyword>Health service research</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Germany</keyword>
  <keyword>Palliative treatment</keyword>
  <keyword>Palliative care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

